Takeda Pharmaceutical (TAK) Buildings (2017 - 2019)

Takeda Pharmaceutical (TAK) posted quarterly Buildings of $1.1 billion for Q1 2019, down 61.19% quarter-over-quarter from $2.9 billion in Q4 2018.

Takeda Pharmaceutical (TAK) Buildings (2017 - 2019) Analysis & Trends

Takeda Pharmaceutical's Buildings history runs 3 years deep, the most recent figure standing at $1.1 billion for Q1 2019.

In Q1 2019, Buildings changed N/A year-over-year to $1.1 billion; the TTM figure through Mar 2019 stood at $1.1 billion (changed N/A YoY), while the FY2019 annual figure was $1.1 billion, changed N/A from the prior year.
Buildings for Q1 2019 stood at $1.1 billion, down from $2.9 billion in the prior quarter.
The five-year high for Buildings was $2.9 billion in Q4 2018, with the low at $1.1 billion in Q1 2019.
The 3-year median for Buildings is $1.9 billion (2017), against an average of $2.0 billion.
Peak annual rise in Buildings reached 51.69% in 2018, while the deepest fall reached 51.69% in 2018.
Takeda Pharmaceutical's Buildings stood at $1.9 billion in 2017, then surged by 51.69% to $2.9 billion in 2018, then tumbled by 61.19% to $1.1 billion in 2019.
Business Quant data shows TAK's Buildings at $1.1 billion in Q1 2019, $2.9 billion in Q4 2018, and $1.9 billion in Q4 2017.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Haleon	44.07 Bn	43.10 Bn	-
2	Teva Pharmaceutical Industries	43.42 Bn	39.76 Bn	2.15 Bn
3	Zoetis	31.86 Bn	30.18 Bn	1.05 Bn
4	Takeda Pharmaceutical	28.77 Bn	22.98 Bn	5.10 Bn
5	United Therapeutics	22.29 Bn	19.63 Bn	683.80 Mn
6	Viatris	18.78 Bn	17.89 Bn	1.46 Bn
7	Neurocrine Biosciences	15.66 Bn	15.27 Bn	935.80 Mn
8	Elanco Animal Health	11.91 Bn	11.38 Bn	798.00 Mn
9	Dr Reddys Laboratories	10.16 Bn	10.00 Bn	-
10	Alkermes	8.20 Bn	7.55 Bn	397.90 Mn

Download Data